Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Hauschild, Axel; Dummer, Reinhard; Schadendorf, Dirk; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Lesimple, Thierry; Plummer, Ruth; Dasgupta, Kohinoor; Haas, Tomas; Shilkrut, Mark; Gasal, Eduard; Kefford, Richard; Kirkwood, John M; Long, Georgina V (2018). Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma. Journal of Clinical Oncology:JCO1801219.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Eggermont, Alexander M M; Suciu, Stefan; Testori, Alessandro; Santinami, Mario; Kruit, Wim H J; Marsden, Jeremy; Punt, Cornelis J A; Salès, François; Dummer, Reinhard; Robert, Caroline; Schadendorf, Dirk; Patel, Poulam M; de Schaetzen, Gaetan; Spatz, Alan; Keilholz, Ulrich (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of Clinical Oncology, 30(31):3810-3818.

This list was generated on Fri Apr 19 12:47:44 2019 CEST.